Nuclear medicine in the era of genomics and proteomics: lessons from annexin V.
In the past decade, genomics and proteomics have begun to develop many new targets for potential diagnostic and therapeutic agents. Among the life sciences, nuclear medicine is also deeply involved in the field of clinical investigation. Experience with radiolabeled annexin V highlights the many steps required to translate a good basic-science concept into the clinical setting. This model also emphasizes the value of synergy between basic and medical specialties in developing and optimizing a clinically useful product initially derived from basic investigation.
Belhocine
Tarik Z
TZ
Department of Nuclear Medicine, Jules Bordet Cancer Institute, Brussels, Belgium. tarik.bel@swing.be
Tait
Jonathan F
JF
Vanderheyden
Jean-Luc
JL
Li
Chun
C
Blankenberg
Francis G
FG
D017304:Annexin A5 / Q000737:chemistry / Q000493:pharmacokinetics*; D017209:Apoptosis / Q000502:physiology; D006801:Humans; D007553:Isotope Labeling; D007668:Kidney / Q000000981:diagnostic imaging*; D008099:Liver / Q000000981:diagnostic imaging*; D008958:Models, Molecular; D009683:Nuclear Medicine; D011877:Radionuclide Imaging; D013154:Spleen / Q000000981:diagnostic imaging
D017304:Annexin A5